Renal transplantation in systemic lupus erythematosus: one center's experience.

David Roth, M. Milgrom, V. Esquenazi, J. Strauss, Gaston E Zilleruelo, J. Miller

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.

Original languageEnglish
Pages (from-to)367-374
Number of pages8
JournalAmerican Journal of Nephrology
Volume7
Issue number5
StatePublished - Dec 1 1987

Fingerprint

Systemic Lupus Erythematosus
Kidney Transplantation
Kidney
Chronic Kidney Failure
Allografts
Dialysis
Creatinine
Transplants
Antinuclear Antibodies
Graft Survival
Antigen-Antibody Complex
Biopsy
DNA
Serum
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Roth, D., Milgrom, M., Esquenazi, V., Strauss, J., Zilleruelo, G. E., & Miller, J. (1987). Renal transplantation in systemic lupus erythematosus: one center's experience. American Journal of Nephrology, 7(5), 367-374.

Renal transplantation in systemic lupus erythematosus : one center's experience. / Roth, David; Milgrom, M.; Esquenazi, V.; Strauss, J.; Zilleruelo, Gaston E; Miller, J.

In: American Journal of Nephrology, Vol. 7, No. 5, 01.12.1987, p. 367-374.

Research output: Contribution to journalArticle

Roth, D, Milgrom, M, Esquenazi, V, Strauss, J, Zilleruelo, GE & Miller, J 1987, 'Renal transplantation in systemic lupus erythematosus: one center's experience.', American Journal of Nephrology, vol. 7, no. 5, pp. 367-374.
Roth D, Milgrom M, Esquenazi V, Strauss J, Zilleruelo GE, Miller J. Renal transplantation in systemic lupus erythematosus: one center's experience. American Journal of Nephrology. 1987 Dec 1;7(5):367-374.
Roth, David ; Milgrom, M. ; Esquenazi, V. ; Strauss, J. ; Zilleruelo, Gaston E ; Miller, J. / Renal transplantation in systemic lupus erythematosus : one center's experience. In: American Journal of Nephrology. 1987 ; Vol. 7, No. 5. pp. 367-374.
@article{3dbed55a918f4f1c8a9aadf63a8be195,
title = "Renal transplantation in systemic lupus erythematosus: one center's experience.",
abstract = "A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84{\%}, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.",
author = "David Roth and M. Milgrom and V. Esquenazi and J. Strauss and Zilleruelo, {Gaston E} and J. Miller",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "7",
pages = "367--374",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "5",

}

TY - JOUR

T1 - Renal transplantation in systemic lupus erythematosus

T2 - one center's experience.

AU - Roth, David

AU - Milgrom, M.

AU - Esquenazi, V.

AU - Strauss, J.

AU - Zilleruelo, Gaston E

AU - Miller, J.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.

AB - A retrospective analysis of 15 renal transplant patients with end-stage renal disease (ESRD) secondary to systemic lupus erythematosus (SLE) was performed. Overall actuarial patient and graft survival at 6 years was 93 and 84%, respectively. Recipients of HLA-identical kidneys did not appear to be at increased risk of allograft failure due to rejection or recurrent disease. Two biopsy-proven cases of recurrent lupus involving the allograft were observed and are discussed. Those patients currently experiencing excellent graft function (creatinine less than 2 mg/dl) had a significantly longer pretransplantation dialytic interval than the group whose most recent serum creatinine exceeds 2 mg/dl (or returned to dialysis). Posttransplantation monitoring of antinuclear antibody, antidouble-stranded DNA, C3, C4, and circulating immune complexes was not predictive of renal or extrarenal disease activity. Renal transplantation should be considered an excellent therapeutic modality for the lupus patient with ESRD, although an interim period on dialysis of at least 1 year seems warranted.

UR - http://www.scopus.com/inward/record.url?scp=0023515316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023515316&partnerID=8YFLogxK

M3 - Article

C2 - 3324763

AN - SCOPUS:0023515316

VL - 7

SP - 367

EP - 374

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 5

ER -